DYN (STOCKS)
Dyne Therapeutics, Inc. Common Stock
$25.960000
-0.210000 (-0.80%)
Prev close: $26.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- John G. Cox
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,025.60M
- Employees
- 206
- P/E (TTM)
- -7.85
- P/B (TTM)
- 6.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
12
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-1.08 | $-0.76 | -0.3218 | -42.44% |
|
Mar 2026 (Q1)
|
$-0.73 | $-0.78 | +0.0508 | +6.51% |
|
Dec 2025 (Q4)
|
$-0.76 | $-0.78 | +0.0177 | +2.28% |
|
Sep 2025 (Q3)
|
$-0.76 | $-0.85 | +0.0857 | +10.13% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $536.96M |
| Research and Development | $445.71M |
| Other Operating Expenses | $91.25M |
| Operating Income/Loss | -$536.96M |
| Income/Loss From Continuing Operations After Tax | -$519.41M |
| Income/Loss From Continuing Operations Before Tax | -$519.41M |
| Net Income/Loss | -$519.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$519.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$519.41M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.30 |
| Diluted Earnings Per Share | -$3.30 |
| Assets | $994.01M |
| Current Assets | $937.89M |
| Noncurrent Assets | $56.12M |
| Fixed Assets | $24.56M |
| Other Non-current Assets | $31.57M |
| Liabilities | $291.86M |
| Current Liabilities | $78.03M |
| Accounts Payable | $12.15M |
| Wages | $11.95M |
| Other Current Liabilities | $53.93M |
| Noncurrent Liabilities | $213.83M |
| Long-term Debt | $199.33M |
| Other Non-current Liabilities | $14.51M |
| Equity | $702.15M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $702.15M |
| Liabilities And Equity | $994.01M |
| Net Cash Flow From Operating Activities | -$477.82M |
| Net Cash Flow From Operating Activities, Continuing | -$477.82M |
| Net Cash Flow From Investing Activities | -$44.17M |
| Net Cash Flow From Investing Activities, Continuing | -$44.17M |
| Net Cash Flow From Financing Activities | $713.47M |
| Net Cash Flow From Financing Activities, Continuing | $713.47M |
| Net Cash Flow | $191.48M |
| Net Cash Flow, Continuing | $191.48M |
| Comprehensive Income/Loss | -$519.40M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$520.01M |
| Other Comprehensive Income/Loss | -$286.59M |